HER2 Breast Cancer

Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.

Research reveals that clinical stage significantly influences survival rates in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

PHESGO reduced patient infusion time from 90 minutes to as few as 5, enhancing patient experience while maintaining efficacy and safety.

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

Trastuzumab deruxtecan shows promising efficacy in treating HER2-positive metastatic breast cancer with brain metastases, offering hope for challenging cases.

Research reveals HER2-negative breast cancer shows higher pCR rates than HER2-low, influencing neoadjuvant chemotherapy strategies for early-stage patients.

Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

Research reveals that combining radiotherapy or immune-modulating drugs with CDK4/6 inhibitors enhances treatment efficacy in HR+/HER2– breast cancer.

The data revealed that only 75% of patients receive HER2-targeting therapies.

Ribociclib in combination with a nonsteroidal aromatase inhibitor (NSAI) improved invasive disease-free survival (iDFS) while allowing for better quality of life in hormone receptor-positive (HR+)/human epidermal growth receptor 2-negative (HER2−) early breast cancer.

About 64.1% of patients receiving taxane, trastuzumab, and pertuzumab (THP) without carboplatin had pathological complete response rates (pCRs).

Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.

Compared with standard of care, camizestrant in combination with a CDK4/6 inhibitor shows promise in enhancing progression-free survival (PFS) for patients with advanced breast cancer.

Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.

Zongertinib shows significant benefits in managing symptoms and improving quality of life for patients with HER2-mutated non-small cell lung cancer.

Trastuzumab deruxtecan (T-DXd) yielded favorable outcomes and improved survival rates.

The data were presented at the ESMO Breast Cancer 2025 Annual Meeting.

Studies suggest that prolonged activation of MUC1-C encourages disease progression.

New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%.

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

Patients in both arms achieved statistically significant rates of compliance up to 97%.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.

The meaningful results were reported in the DESTINY-Breast09 trial.

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

The data showed improvements in overall response rates, progression-free survival, and duration of response.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.